ENTRY       D11876                      Drug
NAME        Efgartigimod alfa (USAN/INN);
            Efgartigimod alfa (genetical recombination) (JAN);
            Efgartigimod alfa-fcab;
            Vyvgart (TN)
PRODUCT     VYVGART (argenx US)
FORMULA     C2310H3554N602O692S14
EXACT_MASS  51247.7506
MOL_WEIGHT  51279.464
SEQUENCE    DKTHTCPPCP APELLGGPSV FLFPPKPKDT LYITREPEVT CVVVDVSHED PEVKFNWYVD
            GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
            GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
            DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALKFHYTQKS LSLSPGK
            (Disulfide bridge: 6-6', 9-9', 41-101, 147-205, 41'-101', 147'-205')
  TYPE      Peptide
REMARK      Therapeutic category: 6399
            ATC code: L04AA58
            Product: D11876<JP/US>
            Product (mixture): D12684<US>
EFFICACY    Autoimmune disease treatment
  DISEASE   Generalized myasthenia gravis (AChR antibody positive) [DS:H01594]
COMMENT     Treatment of IgG-driven autoimmune diseases
TARGET      FCGRT [HSA:2217] [KO:K24019]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA58 Efgartigimod alfa
                  D11876  Efgartigimod alfa (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antimyasthenic Agents
              Efgartigimod Alfa
               D11876  Efgartigimod alfa (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D11876  Efgartigimod alfa (USAN/INN); Efgartigimod alfa (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Immune system
                FCGRT
                 D11876  Efgartigimod alfa (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11876
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11876
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11876
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11876
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D11876
DBLINKS     CAS: 1821402-21-4
///
